多発性硬化症治療学講座 平成28年（2016年）
論文
〔原著〕
Zeka B, Hastermann M, Kaufmann N, Schanda K, Pende M, Misu T, Rommer P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl M, Lassmann H, Bradl M. Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathologica Communications. 201608; 4(1):82.
Pandit L, Sato DK, Mustafa S, Takahashi T, D'Cunha A, Malli C, Sudhir A, Fujihara K. Serological markers associated with neuromyelitis optica spectrum disorders in South India. Annals of Indian Academy of Neurology. 2016; 19(4):505-509.
Nishiyama S, Misu T, Nuriya M, Takano R, Takahashi T, Nakashima I, Yasui M, Itoyama Y, Aoki M, Fujihara K. Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica. Biochemistry and Biophysics Reports. 2016; 7:45-51.
Huang P, Takai Y, Kusano-Arai O, Ramadhanti J, Iwanari H, Miyauchi T, Sakihama T, Han JY, Aoki M, Hamakubo T, Fujihara K, Yasui M, Abe Y. The Binding Property of a Monoclonal Antibody Against the Extracellular Domains of Aquaporin-4 Directs Aquaporin-4 Toward Endocytosis. Biochemistry and Biophysics Reports. 2016; 7:77-83.
Miyazaki-Komine K, Takai Y, Huang P, Kusano-Arai O, Iwanari H, Misu T, Koda K, Mitomo K, Sakihama T, Toyama Y, Fujihara K, Hamakubo T, Yasui M, Abe Y. High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody, NMO-IgG. British Journal of Pharmacology. 2016; 173:103-114.
Oji S, Tanaka S, Kojima M, Fukaura H, Mori M, Takahashi T, Fujihara K, Nomura K. Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for non-responders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: implication for early institution of plasmapheresis. Clinical & Experimental Neuroimmunology. 2016; 7:272-280.
Adachi T, Yasui K, Takahashi T, Fujihara K, Watanabe Y, Nakashima K. Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. Internal Medicine. 201605; 55(10):1351-1354.
Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, Nishiyama S, Kurosawa K, Misu T, Nakazawa T, Aoki M, Fujihara K. Lesion length of optic neuritis impacts visual prognosi in neuromyelitis optica. Journal of Neuroimmunology. 2016; 293:28-33.
Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, Sato DK, Takahashi T, Nakazawa T, Aoki M, Fujihara K. Different etiologies and prognoses of optic neuritis in demyelinating diseases. Journal of Neuroimmunology. 2016; 299:152-157.
Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M. MRI and retinal abnormalities in isolated optic neuritis with myelin-oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. Journal of Neurology, Neurosurgery, and Psychiatry. 2016; 87(4):446-448.
Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 201601; 87(11):1257-1259.
Ogasawara M, Meguro A, Sakai T, Mizuki N, Takahashi T, Fujihara K, Tsuneoka H, Shikishima K. Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population. Japanese Journal of Ophthalmology. 201605; 60(3):198-205.
Siritho S, Sato DK, Kaneko K, Fujihara K, Prayoonwiwat N. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Multiple Sclerosis Journal. 2016; 22(7):964-968.
Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida KI, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira JI. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal. 2016; 22(10):1337-1348.
Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J, Takai Y, George J, Kitley J, Santos ME, Nour JM, Cheng F, Kuroda H, Misu T, Martins-da-Silva A, DeLuca GC, Vincent A, Palace J, Waters P, Fujihara K, Leite MI. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology. 201601; 86(1):79-87.
Takai Y, Misu T, Nishiyama S, Ono H, Kuroda H, Nakashima I, Saito R, Kanamori M, Sonoda Y, Kumabe T, Mugikura S, Watanabe M, Aoki M, Fujihara K. Hypoxia-like tissue injury and glial response contribute to Balo’s concentric lesion development. Neurology. 201611; 87(19):2000-2005.
Higuchi O, Nakane S, Sakai W, Maeda Y, Niino M, Takahashi T, Fukazawa T, Kikuchi S, Fujihara K, Matuo H. Lack of KIR41 autoantibodies in Japanese patients with MS and NMO. Neurology Neuroimmunology & Neuroinflammation. 201607; 3(5):263.
Tateyama M, Shibuya S, Sato H, Fujihara K, Aoki M. Pseudo-perifascicular atrophy in the healing phase of Jo-1 antisynthetase syndrome. Neuromuscular Disorders. 201608; 26(8):521-522.
Oji S, Nicolussi E, Kaufmann N, Schanda K, Fujihara K, Illes Z, Reindl M, Lassmann H, Bradl M. Experimental neuromyelitis optica induces a type I interferon signature in the spinal cord. PLOS ONE. 2016; 11(3):e0151244.
[ このページのトップへ ]
〔総説等〕
Ochi H, Fujihara K. Demyelinating diseases in Asia. Current Opinion in Neurology. 201606; 29(3):222-228.
Passos G, Sato D, Becker J, Fujihara K. Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications". Mediators of Inflammation. 2016; 2016:5314541.
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Multiple Sclerosis Journal. 2016; 22(7):862-872.
[ このページのトップへ ]
著書・訳書
藤原一男. 多発性硬化症治療薬. In: 福井次矢 監修. Pocket Drugs 2016. 東京: 医学書院; 2016. p.71-76.
藤原一男. アフェレシス療法. In: 阿部康二 編著. ポケット版 神経内科 検査・処置マニュアル. 東京: 新興医学出版社; 2016. p.193-198.
藤原一男. 脳・脊髄脱髄疾患. In: 平山惠造 監修. 臨床神経内科学(改訂6版). 東京: 南山堂; 2016. p.447-459.
藤原一男. 抗アクアポリン4抗体検査. In: 平山惠造 監修. 臨床神経内科学(改訂6版). 東京: 南山堂; 2016. p.842-844.
[ このページのトップへ ]
研究発表等
〔シンポジウム〕
Fujihara K. Optic Neuritis: Pathology and Differential Diagnosis. 17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS); 20160624; Sao Paulo, Brazil.
[ このページのトップへ ]
〔特別講演〕
藤原一男. 私のNMOSD, MS研究史. 埼玉医科大学神経内科萬象会; 20161108; 川越.
[ このページのトップへ ]
〔招待講演〕
Fujihara K. Neuromyelitis optica spectrum disorders (NMOSD) and MOG-IgG. The 2nd Chinese International Summit Meeting of Neuroinfection, Immunity and Cerebrovascular Diseases; 20160521; Beijing, China.
Fujihara K. NMO/NMO Spectrum Diseases (in honor of Eugene Devic), IX International consensus diagnostic criteria of NMOSD. Clinical Neuroimmunology Symposium; 20160603; Kusadasi, Turkey.
Fujihara K. Critical Comparative Analysis of the Revised 2006 Criteria and the International Consensus Criteria (2015) for Diagnosis of NMOSD. 17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS); 20160623; Sao Paulo, Brazil.
Fujihara K. Epidemiology of Multiple Sclerosis in Asia: An Overview (PACTRIMS). 17th Annual Meeting of Brazilian Committee on Treatment and Research in Multiple Sclerosis (BCTRIMS); 20160623; Sao Paulo, Brazil.
Fujihara K. The Diagnostic Challenge of Multiple Sclerosis. UCB APAC MS Summit; 20160716; Seoul, Korea.
Fujihara K. MS (PACTRIMS) 1 - Classic Multiple Sclerosis Classic MS: Update on Pathogenesis. 15th Asian and Oceanian Congress of Neurology (AOCN); 20160820; Kuala Lumpur, Malaysia.
Fujihara K. Multiple Sclerosis (PACTRIMS) 2 - MS Related Disorder Implications of The New Diagnostic Criteria of NMOSD. 15th Asian and Oceanian Congress of Neurology (AOCN); 20160820; Kuala Lumpur, Malaysia.
Fujihara K. Neuromyelitis Optica Spectrum Disorders Pathomechanisms of AQP4-Ig+, MOG-IgG+ and Seronegative Diseases. 32th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS); 20160914; London, United Kingdom.
Fujihara K. New trial designs and treatment approach for NMO. 32th Congress of European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS); 20160915; London, United Kingdom.
Fujihara K. Autoimmune neurologic disorders, Aquaporin 4 antibody in neuromyelitis optica spectrum disorders. The 13th International Workshop on Autoantibodies and Autoimmunity; 20161012; Kyoto, Japan.
Fujihara K. Progressive MS in Asia. The 9th Annual Congress of Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS); 20161027; Bangkok, Thailand.
Fujihara K. Using MRI to diagnose MS and related disorders Case examples of other MS mimics. The 9th Annual Congress of Pan-Asian Committee on Treatment and Research in Multiple Sclerosis (PACTRIMS); 20161028; Bangkok, Thailand.
藤原一男. 多発性硬化症と関連疾患：診療に役立つ治療と病態. 第2回四国MSセミナー; 20160129; 高知.
藤原一男. MSとNMOの鑑別ポイント. イムセラWEBセミナー; 20160219; 東京.
藤原一男. 多発性硬化症の早期診断と治療. 第3回フィンゴリモドフォーラム; 20160226; 米子.
藤原一男. 多発性硬化症と視神経脊髄炎の診断と治療. 第97回日本神経学会東北地方会ランチョンセミナー; 20160305; 仙台.
藤原一男. NMOと抗MOG抗体. 多発性硬化症講演会 in Kansai; 20160326; 大阪.
藤原一男. 多発性硬化症と視神経脊髄炎の診断と治療. 日本医師会医学講座 (ラジオNIKKEI); 20160414; 東京.
藤原一男. 視神経脊髄炎の新しい診断基準. 第57回日本神経学会学術大会教育コース; 20160518; 神戸.
藤原一男. MSの鑑別診断と薬剤選択について. 日本神経学会第105回近畿地方会ランチョンセミナー; 20160702; 京都.
藤原一男. そこが知りたい！MS治療の最先端. 茨城県難病団体連絡協議会医療講演会・相談会・交流会; 20160925; 水戸.
藤原一男. 多発性硬化症の鑑別診断と治療の選択. 第28回日本神経免疫学会学術集会ランチョンセミナー; 20160930; 長崎.
藤原一男. 多発性硬化症と視神経脊髄炎に関連したバイオマーカー：AQP4抗体とMOG抗体. 第56回日本臨床化学会年次学術集会シンポジウム; 20161203; 熊本.
[ このページのトップへ ]
受託・共同研究・補助等実績一覧
| 年度 | 実施形態 | 研究テーマ | 補助金・資金制度名／種別 | 相手機関名 | 代表研究者 | 共同研究者一覧 |
|---|---|---|---|---|---|---|
| 平成28 | 補助・助成 | エビデンスに基づいた神経免疫疾患の早期診断基準・重症度分類・治療アルゴリズムの確立 | 厚生労働科学研究費補助金 疾病・障害対策研究分野 難治性疾患等政策研究（難治性疾患政策研究） | 厚生労働省 | 松井 真 | 池田修一, 荻野美恵子, 梶 龍兒, 神田 隆, 吉良潤一, 楠 進, 久保田龍二, 桑原 聡, 清水 潤, 清水優子, 鈴木則宏, 園生雅弘, 祖父江元, 竹内英之, 田中正美, 中辻裕司, 新野正明, 河内 泉, 野村恭一, 酒井康成, 藤原一男, 松尾秀徳, 横田隆徳, 木村政勝, 山村 隆, 吉川弘明, 渡邊 修 |
| 平成28 | 国内共同研究 | HAMの革新的な医薬品等の開発促進に関する研究 | 難治性疾患実用化研究事業 | 日本医療研究開発機構(AMED) | 山野嘉久 | 長谷川泰弘, 新野正明, 藤原一男, 中川正法, 竹之内徳博, 永井将弘, 吉良潤一, 中村龍文, 髙嶋 博, 渡嘉敷崇, 米澤久司, 坪井義夫, 髙田礼子, 齊藤峰輝, 外丸詩野, 植田幸嗣, 松田文彦, 井上永介 |
| 平成28 | 補助・助成 | 非典型的多発性硬化症の臨床・病態解析 | 科学研究費補助金／基盤研究(B) | 日本学術振興会 | 藤原一男 |
[ このページのトップへ ]